Carfilzomib combinations in ENDEAVOR and FORTE

Deep molecular response to gilteritinib in CHRYSALIS trial

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Diverse T lymphocyte population fights leukaemia more effectively

Delayed exposure to common infections causes acute childhood leukaemia

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL

Improving outcomes for oestrogen receptor positive breast cancer

Translational research: from bench to bedside

European guidelines for breast cancer treatment

The European Alliance for Personalised Medicine

EUPATI and patient involvement

ESMO ranking of the clinical benefits of new drugs